Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies

Dermatol Online J. 2011 Apr 15;17(4):14.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acitretin / therapeutic use
  • Adalimumab
  • Adrenal Cortex Hormones / therapeutic use
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Calcitriol / analogs & derivatives
  • Calcitriol / therapeutic use
  • Cyclosporine / therapeutic use
  • Dermatologic Agents / therapeutic use*
  • Drug Therapy, Combination
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / therapeutic use
  • Infliximab
  • Methotrexate / therapeutic use
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Tacrolimus / analogs & derivatives
  • Tacrolimus / therapeutic use
  • Treatment Outcome
  • Ustekinumab

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • calcipotriene
  • pimecrolimus
  • Cyclosporine
  • Infliximab
  • Ustekinumab
  • Calcitriol
  • Adalimumab
  • Acitretin
  • Etanercept
  • Tacrolimus
  • Methotrexate